News Column

First US Patent for Vaccine Treatment of Obesity Is Awarded to Braasch Biotech LLC

Apr 30 2013 12:00AM

Marketwire

LogoTracker

GARRETSON, SD -- (Marketwired) -- 04/30/13 -- Braasch Biotech LLC, a biopharmaceutical company pioneering a new field of anti-somatostatin vaccines, today announced the company was assigned US Patent 8,425,914 for vaccination methods in the treatment of obesity.

The patent issued on April 23, 2013 for Methods for enhanced somatostatin immunogenicity in the treatment of obesity, is the first patent issued by the United States Patent and Trademark Office (USPTO) for treatment of phenotypic obesity by vaccination.

The prevalence of obesity has risen dramatically in the past decade and is a very serious health problem in the United States, United Kingdom and elsewhere in the world. Obesity is a risk factor for high blood pressure, heart disease, stroke, gall bladder disease, breast cancer, prostate cancer, colon cancer, and type-2 diabetes. According to the WHO, currently 1 in 5 adults is overweight with at least a third of them obese. By the year 2030, at least one half of the US population will be obese, if current trending persists.

"Our work on treatment of obesity by the use of our paradigm-shifting approach has previously been recognized by the Journal of Animal Science and Biotechnology, Endocrine News, Science and the Obesity Society," stated Jeralyn Kay Haffer, CEO and Chairman of Braasch. "We are now pleased the USPTO also has recognized the vaccine's novelty and commercial utility in the fight against human obesity." Additional patent applications for the Company's obesity technologies are issued or pending in a number of other countries including Europe, Mexico, South Africa, Brazil, Canada, China, India, Japan and Korea.

Braasch's intellectual property portfolio includes multiple patent families with issued or pending claims directed to utility of anti-somatostatin vaccine technologies, Somatovac® for multiple metabolic challenges.

About Braasch Biotech

Braasch Biotech is pioneering a new field of therapeutic approaches utilizing Somatovac® technologies. To date, Braasch has multiple regulatory submissions in progress with the US and international regulatory bodies on the use of vaccines in metabolic regulation. Braasch Biotech is a privately held biopharmaceutical with corporate offices in South Dakota.

For more information on Braasch Biotech, please email info@braaschbiotech.com or visit www.braaschbiotech.com.



Contact Information
Jeralyn Kay Haffer
CEO and Chairman
Tel. 605-376-8752
Fax. 605-594-6256
Email Contact





Source: Marketwire


Story Tools






HispanicBusiness.com Facebook Linkedin Twitter RSS Feed Email Alerts & Newsletters